Skip navigation
Watchlist Sponsored By :


Current DateTime: 01:32:09 02 Dec 2009
LinksList Documentid: 24355697
  • The Cost of True Love

      In the popular holiday song "The 12 Days of Christmas," the cost of gifts - from the 12 drummers drumming to a partridge in a pear tree - is quite pricey.

  • Runway Angels

      The superbowl of fashion shows, models walk down the runway at the 2009 Victoria's Secret Show.

  • Smartphone Guide

      Here's a need-to-know guide to nine devices, based on features, price, network and platform.

FEATURED QUIZZES


Current DateTime: 01:32:09 02 Dec 2009
LinksList Documentid: 33793611
  • Test Your Google IQ

      How much do you know about the most popular search engine in the world? Take the following quiz and find out.

  • A Healthier & Wealthier You

      Take the following quiz and find out how much you know about the impact of obesity on the health of the U.S. economy.

  • How Well Do You Know Your Bird?

      Let's talk turkey. Test your turkey knowledge and perhaps pick up a bit of trivia to trot out at your holiday meal.


Current DateTime: 01:32:09 02 Dec 2009
LinksList Documentid: 24890560
  • Predictions '10

      After a brutal 2009, we're all looking forward to 2010. Here's what our bloggers expect.

  • Holiday Central

      There are plenty of reasons to believe that this Christmas holiday season will not be as bad for retailers as last year.

  • Winterizing Your Portfolio

      If 2009 was the winter of our discontent, will 2010 be a winter wonderland for investors? A lot depends on the recovery—or lack thereof.

powered by digg
Battered Glaxo Faces Calls to Boost Cash Returns
By: Reuters | 05 Jun 2007 | 12:26 PM ET
Text Size

GlaxoSmithKline, its shares off 12% in the past fortnight due to a safety scare over diabetes drug Avandia, is under growing pressure to increase cash returns to mollify shareholders.

Dresdner Kleinwort was the latest brokerage on Tuesday to highlight the potential for Glaxo [GSK  Loading...      ()   ] to increase leverage to the benefit of investors.

Analyst Tero Weckroth said Glaxo had most to gain of any major European drugmaker from adopting some of the techniques of private equity.

By leveraging the balance sheet, he calculated shareholders would receive a 50 to 75% return from dividends alone by 2015 and would still be left with pipeline upside from a R&D-driven pharmaceutical company.

His report follows a similar call from UBS earlier this year for drugmakers to increase gearing.

Craig Maxwell of JP Morgan, meanwhile, believes Glaxo now needs to look at its strategic options on a number of fronts.

Maxwell wrote in a note last week that Glaxo could comfortably lift the dividend payout ratio to 60 from 53% last year, thereby increasing the dividend yield from 3.7 in 2006 to 4.5% in 2008.

It could also go out and buy AstraZeneca [AZN  Loading...      ()   ] , a long-rumored idea, although its British rival's depleted pipeline might make this unattractive.

But the most appealing option for Europe's biggest drugmaker in its current predicament might be to sell off consumer healthcare, Maxwell believes.

Consumer Healthcare Selloff?

In the past, Glaxo has always insisted it is committed to consumer health, which includes non-prescription medicines, as well as oral care and nutritional drinks.

But a sell-off for perhaps 14.3 billion pounds ($28.50 billion) could be significantly accretive, Maxwell argued.

Other analysts suggested a sale of the drinks business alone -- grouping Lucozade, Ribena and Horlicks -- might be more acceptable to Glaxo management, although with annual turnover of 400 million pounds this is only a small part of consumer health.

A Glaxo spokeswoman declined to comment on the latest analyst notes but said the company was focused on its share buyback program as a way to return to cash, adding that dividend payouts were also increased last year.

Chief Executive Jean-Pierre Garnier acknowledged in April that some investors wanted the group to gear up its balance sheet and return more cash, but he said Glaxo was already doing this.

The company increased its debt by around 500 million pounds to 3 billion pounds in the first quarter and plans to double its share buyback to 2 billion pounds this year.

Drugmakers have traditionally run conservative balance sheets with little debt but Dresdner's Weckroth said their recent woes, including an Avandia scare that Glaxo says is unfounded, had prompted more investors to question the strategy.

"For the sector as a whole, the basic message is clear -- if there is no increase in leverage in the near future for Big Pharma, then shareholders will demand to know why," he said.

Copyright 2009 Reuters. Click for restrictions.
Tools:
Print EmailAdd This share icon
  • digg share

CNBC HIGHLIGHTS

  • Will the Fed raise rates? Will the dollar continue its slide? CNBC experts weigh in on the year ahead.
  • Lloyd Blankfein
  • Goldman Sachs has forbidden employees from gathering in private holiday parties of 12 or more.
  • Lemonade stand
  • Do you have what it takes to run your own business? Ask yourself these questions.
  • Heavily armed pirates in Somalia have set up a sort of stock exhange to fund their hijackings.
  • Since its launch in 1998, Google has become a primary force on the Internet. How much do you know about the company?
  • typewriter
  • A famed author has written all his work on an old typewriter that is now up for auction. The NYT reports.
ADD COMMENTS
Remaining characters


Current DateTime: 01:03:47 02 Dec 2009
LinksList Documentid: 29778428

Current DateTime: 01:02:15 02 Dec 2009
LinksList Documentid: 29779196

Current DateTime: 01:02:15 02 Dec 2009
LinksList Documentid: 29779199

Current DateTime: 01:02:15 02 Dec 2009
LinksList Documentid: 29779198
  Data is a real-time snapshot  *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc.  All Rights Reserved.
A Division of NBC Universal
Thomson ReutersThomson Reuters